Stem Cell Treatment for Acute Lymphoblastic Leukemia in Adults

Author:

Gallicchio Vincent S

Abstract

Stem cell therapy used to treat Acute Lymphoblastic Leukemia in adults (ALL) has been one of the more promising uses of stem cells and has large implications on the survival rate of adults with ALL. While the survival rate of ALL remains relatively low at an estimated 20% to 30% in adults, stem cell as an adjunct therapy has shown promising results. Historically, ALL has a high rate of recurrence in adults and one study aims to assess the effectiveness of hematopoietic stem cell therapy in diminishing the rates of recurrence. Stem cell therapy for blood diseases is most found in the form of an allogeneic bone marrow transplant, which includes transplantation of HSCs from a donor. It can help to stimulate the body to produce healthy blood cells and thereby keep the disease at bay. The study concluded that HSCT increases the survival rate of adults with ALL and that it should be considered if a patient has a viable donor available. We see that multiple other studies come to similar conclusions, such as one study that found increased long-term disease-free survival can be achieved through stem cell therapy. A culmination of incredible research excites the idea of an extraordinary step forward in helping to cure those suffering from acute lymphoblastic leukemia and improve long-term, disease-free survival.

Publisher

Athenaeum Scientific Publishers

Reference22 articles.

1. https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-statistics.html#:~=Overall%2C%20about%204%20of%20every,is%20about%201%20in%201%2C000 [Last accessed on: August 6, 2024]

2. Gale RP, Kersey JH, Bortin MM, Dicke KA, Good RA, Zwaan FE, et al. Bone-marrow transplantation for acute lymphoblastic leukaemia. Lancet. 1983;7:663-7.

3. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present and future. Stem Cell Res Ther. 2019;10:68.

4. Lee J, Hong S. Hematopoietic stem cells and their roles in tissue regeneration. Int J Stem Cells. 2020;13:1-12.

5. Singh R, Soman-Faulkner K, Sugumar K. Embryology, hematopoiesis. StatPearls. 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3